These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16503742)

  • 1. Efalizumab: a review of events reported during clinical trials and side effects.
    Scheinfeld N
    Expert Opin Drug Saf; 2006 Mar; 5(2):197-209. PubMed ID: 16503742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efalizumab].
    Descamps V
    Ann Dermatol Venereol; 2006; 133(8-9 Pt 1):666-78. PubMed ID: 17053736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab.
    Pincelli C; Henninger E; Casset-Semanaz F
    Arch Dermatol Res; 2006 Dec; 298(7):329-38. PubMed ID: 17021768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trial.
    Hamilton T; Menter A; Caro I; Compton P; Sobell J; Papp KA
    Drug Saf; 2008; 31(8):715-26. PubMed ID: 18636790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efalizumab.
    Wellington K; Perry CM
    Am J Clin Dermatol; 2005; 6(2):113-8; discussion 119-20. PubMed ID: 15799683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
    Lebwohl M; Tyring SK; Hamilton TK; Toth D; Glazer S; Tawfik NH; Walicke P; Dummer W; Wang X; Garovoy MR; Pariser D;
    N Engl J Med; 2003 Nov; 349(21):2004-13. PubMed ID: 14627785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study.
    Tsai TF; Liu MT; Liao YH; Licu D
    J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):345-52. PubMed ID: 18005021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.
    Papp KA; Bressinck R; Fretzin S; Goffe B; Kempers S; Gordon KB; Caro I; Walicke PA; Wang X; Menter A;
    Int J Dermatol; 2006 May; 45(5):605-14. PubMed ID: 16700803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience.
    Langley RG; Carey WP; Rafal ES; Tyring SK; Caro I; Wang X; Wetherill G; Gordon KB
    Clin Ther; 2005 Sep; 27(9):1317-28. PubMed ID: 16291408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. part II.
    Papp KA; Camisa C; Stone SP; Caro I; Wang X; Compton P; Walicke PA; Gottlieb AB
    J Cutan Med Surg; 2005 Dec; 9(6):313-23. PubMed ID: 16699903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasis.
    Gottlieb AB; Miller B; Lowe N; Shapiro W; Hudson C; Bright R; Ling M; Magee A; McCall CO; Rist T; Dummer W; Walicke P; Bauer RJ; White M; Garovoy M
    J Cutan Med Surg; 2003; 7(3):198-207. PubMed ID: 12717587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efalizumab: new drug. Plaque psoriasis: too many unknowns.
    Prescrire Int; 2006 Feb; 15(81):8-11. PubMed ID: 16548097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab.
    Cather JC; Cather JC; Menter A
    Expert Opin Biol Ther; 2003 Apr; 3(2):361-70. PubMed ID: 12662148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exacerbation of psoriasis under efalizumab therapy.
    Rallis E; Verros C; Karanikola E; Valaskatzi A; Papaconstantis M
    J Cutan Med Surg; 2009; 13(2):106-9. PubMed ID: 19298780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis.
    Leonardi CL; Toth D; Cather JC; Langley RG; Werther W; Compton P; Kwon P; Wetherill G; Curtin F; Menter A
    Dermatology; 2006; 213(3):204-14. PubMed ID: 17033169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
    Menter A; Kosinski M; Bresnahan BW; Papp KA; Ware JE
    J Drugs Dermatol; 2004; 3(1):27-38. PubMed ID: 14964744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
    Gordon KB; Papp KA; Hamilton TK; Walicke PA; Dummer W; Li N; Bresnahan BW; Menter A;
    JAMA; 2003 Dec; 290(23):3073-80. PubMed ID: 14679270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
    Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139].
    Ortonne JP; Shear N; Shumack S; Henninger E;
    BMC Dermatol; 2005 Dec; 5():13. PubMed ID: 16359548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efalizumab: continuous therapy for chronic psoriasis.
    Cather JC; Menter A
    Expert Opin Biol Ther; 2005 Mar; 5(3):393-403. PubMed ID: 15833076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.